INNOVATIVE PUBLICATION
Journal of Effective Learning and Sustainable Innovation
Vol.3 №4 (2025). April
innovativepublication.uz

CLINICAL PHARMACOLOGY OF HYPOLIPIDEMIC DRUGS

Rasulov Boburjon Abduqahhorovich
Assistant, Department of Pharmacology, Clinical Pharmacology and Medical Biotechnology, ASMI

Abstract: This article explores the clinical pharmacology of hypolipidemic (lipid-lowering) drugs, which play a pivotal role in the prevention and treatment of atherosclerotic cardiovascular disease. It outlines the pharmacodynamics, pharmacokinetics, classification, indications, and safety profiles of major hypolipidemic agents, including statins, fibrates, bile acid sequestrants, cholesterol absorption inhibitors, PCSK9 inhibitors, and emerging therapies. The article highlights their mechanisms of action, therapeutic applications, and considerations for personalized lipid management.

Keywords: Hypolipidemic drugs, statins, PCSK9 inhibitors, LDL-C reduction, cardiovascular prevention, lipid metabolism, clinical pharmacology.

INTRODUCTION

Dyslipidemia — characterized by elevated levels of low-density lipoprotein cholesterol (LDL-C), triglycerides, or reduced high-density lipoprotein cholesterol (HDL-C) — is a major modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD), the leading cause of mortality globally. Clinical guidelines emphasize aggressive lipid-lowering therapy for both primary and secondary prevention of cardiovascular events. Hypolipidemic drugs, through distinct pharmacological mechanisms, reduce lipid concentrations and improve vascular outcomes. This article reviews the pharmacological principles, mechanisms of action, and clinical applications of the primary classes of lipid-

lowering medications, with attention to efficacy, tolerability, and recent advances in precision therapy.

MATERIALS AND METHODS

Statins are the cornerstone of lipid-lowering therapy. They competitively inhibit HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis. This reduction in intracellular cholesterol leads to upregulation of LDL receptors on hepatocyte surfaces, increasing clearance of circulating LDL-C. Statins also exhibit pleiotropic effects including improvement of endothelial function, reduction of inflammation (lowering CRP), and plaque stabilization.

Commonly prescribed statins include simvastatin, atorvastatin, rosuvastatin, and pravastatin. The pharmacokinetics vary by agent — for instance, atorvastatin and rosuvastatin have longer half-lives and are suitable for once-daily dosing, while simvastatin has greater first-pass hepatic metabolism. Statins are metabolized primarily by CYP3A4 (except pravastatin), which has implications for drug-drug interactions. Adverse effects include myalgia, elevated liver enzymes, and rare but serious rhabdomyolysis. Statins are contraindicated in active liver disease and pregnancy.

RESULTS AND DISCUSSION

Fibrates activate peroxisome proliferator-activated receptor alpha (PPAR-α), a nuclear receptor that upregulates lipoprotein lipase activity, promoting triglyceride catabolism and modestly increasing HDL-C. They are particularly effective in hypertriglyceridemia and mixed dyslipidemia, often seen in metabolic syndrome and type 2 diabetes.

Examples include fenofibrate and gemfibrozil. Fenofibrate is preferred due to its more favorable safety and interaction profile. Fibrates are generally well tolerated but can cause gastrointestinal disturbances, increased creatinine, and — when combined with statins

— a heightened risk of myopathy. Gemfibrozil inhibits glucuronidation of statins, thereby increasing statin plasma levels and toxicity risk [1].

This class includes cholestyramine, colesevelam, and colestipol, which bind bile acids in the intestine, interrupting enterohepatic circulation. Hepatic cholesterol is then diverted toward bile acid synthesis, thereby upregulating LDL receptors and enhancing LDL clearance.

These agents are non-systemic and useful in patients who cannot tolerate statins. However, their bulky dosing regimens and common side effects — including constipation, bloating, and interference with fat-soluble vitamin absorption — often limit adherence. They also reduce absorption of certain drugs, such as warfarin and digoxin, requiring dose separation.

Ezetimibe selectively inhibits the Niemann-Pick C1-like 1 (NPC1L1) transporter in the intestinal brush border, reducing dietary and biliary cholesterol absorption by ~50%. It results in a compensatory increase in hepatic LDL receptor expression and LDL-C clearance.

Ezetimibe is well tolerated and commonly used in combination with statins, especially when high-intensity statins are not tolerated or insufficient. The IMPROVE-IT trial confirmed additional cardiovascular benefit when ezetimibe was added to simvastatin in patients with recent acute coronary syndrome.

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors — such as evolocumab and alirocumab — are monoclonal antibodies that prevent PCSK9 from binding to LDL receptors, thereby preventing receptor degradation and enhancing LDL-C clearance [2].

They are administered via subcutaneous injection every 2–4 weeks and reduce LDL-C by up to 60%. These agents are indicated in familial hypercholesterolemia and in patients with ASCVD requiring further LDL-C lowering beyond what statins and ezetimibe can

achieve. They are generally well tolerated, with nasopharyngitis and injection-site reactions being the most common adverse events. High cost remains a barrier to widespread use.

Several novel agents are under clinical investigation or have recently entered the market:

Bempedoic acid, an ATP citrate lyase inhibitor, reduces hepatic cholesterol synthesis upstream of HMG-CoA reductase. It is activated only in hepatocytes, reducing the risk of muscle-related side effects.

Inclisiran, a small interfering RNA (siRNA), inhibits hepatic PCSK9 synthesis and requires only biannual dosing.

Lomitapide and mipomersen, used in homozygous familial hypercholesterolemia, inhibit lipoprotein production but are limited by hepatic toxicity and injection site reactions [3].

Personalized lipid-lowering therapy is increasingly important, particularly for patients with statin intolerance, polypharmacy, or genetic lipid disorders. Pharmacogenomic testing, including SLCO1B1 genotyping, may help predict statin-associated myopathy risk. Monitoring includes baseline and follow-up lipid profiles, liver enzymes, and, when indicated, creatine kinase (CK) levels.

The clinical application of hypolipidemic drugs extends beyond standardized regimens, requiring adaptation to specific populations that present with unique pharmacodynamic and pharmacokinetic considerations. For instance, elderly patients often have reduced hepatic and renal clearance, polypharmacy risks, and increased susceptibility to adverse drug reactions. In this group, lipid-lowering therapy must be carefully titrated, with attention to drug–drug interactions and muscle-related side effects. Nevertheless, studies such as the PROSPER trial have confirmed the cardiovascular benefit of statin therapy in elderly patients with established vascular disease, supporting its continued use in secondary prevention.

In patients with type 2 diabetes mellitus (T2DM), dyslipidemia is characterized by elevated triglycerides, low HDL-C, and often small dense LDL particles — a profile particularly atherogenic. Statins remain first-line therapy, as shown by the CARDS and HPS trials, which demonstrated significant reductions in major cardiovascular events in diabetic patients irrespective of baseline LDL levels. However, caution is required when combining statins with fibrates in diabetic patients due to potential increased risk of myopathy, especially when renal function is impaired [4].

Chronic kidney disease (CKD) poses another clinical challenge. In non-dialysis-dependent CKD, statins have proven beneficial in reducing atherosclerotic events, while in patients on maintenance dialysis, the benefit is less clear, as seen in the AURORA and 4D trials. Nonetheless, certain hypolipidemic drugs such as pravastatin and fluvastatin — which are less dependent on renal clearance — are considered safer in advanced CKD. Moreover, lipophilic statins should be used with caution in CKD due to potential accumulation and muscle toxicity.

A growing clinical concern is the phenomenon of statin intolerance, most commonly manifested as statin-associated muscle symptoms (SAMS), which may range from mild myalgia to severe rhabdomyolysis. The pathophysiology remains multifactorial, involving impaired mitochondrial function, CoQ10 depletion, and genetic polymorphisms such as SLCO1B1 variants that alter hepatic statin uptake. In confirmed cases, options include switching to a hydrophilic statin (e.g., pravastatin or rosuvastatin), reducing the dose, using alternate-day dosing, or adding non-statin agents such as ezetimibe or PCSK9 inhibitors. Coenzyme Q10 supplementation is sometimes used, though evidence for efficacy in reducing SAMS remains inconclusive.

Beyond lipid-lowering, hypolipidemic drugs — especially statins — possess pleiotropic effects that contribute to their overall cardiovascular benefit. These include anti-inflammatory, antithrombotic, and endothelial-stabilizing properties. Statins downregulate

pro-inflammatory cytokines (e.g., IL-6, TNF-α), reduce C-reactive protein (CRP) levels, improve nitric oxide bioavailability, and attenuate oxidative stress. These effects promote plaque stabilization, reduce the risk of rupture, and improve vascular compliance, partially explaining the rapid risk reduction observed shortly after initiation of statin therapy [5].

CONCLUSION

Hypolipidemic drugs form the pharmacological backbone of cardiovascular risk reduction strategies. Statins remain the first-line agents due to their proven efficacy and mortality benefit, but alternative and adjunctive therapies are essential for patients with specific lipid profiles, comorbidities, or drug intolerance. Understanding the clinical pharmacology of each agent — including mechanism of action, metabolism, adverse effects, and interactions — is key to optimizing lipid management. As new therapies emerge, individualized approaches and adherence to evidence-based guidelines will be vital in achieving lipid targets and improving patient outcomes.

REFERENCES:

1. Grundy, S. M., et al. 2018 AHA/ACC Multisociety Guideline on the Management of Blood Cholesterol. – J Am Coll Cardiol. – 2019. – Vol. 73, №24. – P. e285–e350.
2. Mach, F., et al. ESC/EAS Guidelines for the management of dyslipidaemias: 2019. – Eur Heart J. – 2020. – Vol. 41, №1. – P. 111–188.
3. Ridker, P. M., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. – N Engl J Med. – 2008. – Vol. 359, №21. – P. 2195–2207.
4. Sabatine, M. S., et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. – N Engl J Med. – 2017. – Vol. 376, №18. – P. 1713–1722.
5. Ballantyne, C. M., et al. Efficacy and safety of bempedoic acid added to maximally tolerated statins in patients with hypercholesterolemia. – JAMA. – 2020. – Vol. 324, №8. – P. 747–756.